Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

Self-service data analytics company Gigasheet announced a new digital platform designed to enhance healthcare price ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, describes how his company's ...

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack ...

Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...